| abstract |
Methods and compositions are described for the treatment of cancers with specific tumorigenic driving mutations by administering a CDK4/6 inhibitor in combination with an additional kinase inhibitor, wherein the specific combination provides a beneficial or synergistic inhibitory activity and/or, Delays acquired resistance to additional kinase inhibitors and/or prolongs the efficacy of the kinase inhibitor. |